LBO — KAPIOLANI MED CTR FOR WOMEN & CHILDR
IRR: 16.5% | MOIC: 2.15x
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
16.5%
IRR
2.15x
MOIC
$534.7M
Entry EV
$802.9M
Exit EV
$275.2M
Equity Invested
Sources & Uses
S&UTotal · $534.7M| Item | Amount | % | Distribution |
|---|---|---|---|
| Senior Debt | $207.7M | 38.8% | |
| Sub Debt | $51.9M | 9.7% | |
| Equity | $275.2M | 51.5% | |
| Enterprise Value | $519.2M | 97.1% | |
| Transaction Fees | $15.6M | 2.9% | |
| Total Uses | $534.7M | 100.0% |
Interpretation
INTAt 2.15x MOIC and 16.5% IRR over 5 years, this deal meets the 15-20% range — acceptable with operational upside.
Key drivers: Check the EBITDA bridge to identify highest-probability levers, the debt schedule for leverage trajectory, or the challenge solver to see what breaks the deal.
Returns Waterfall
WFL| Component | Value |
|---|---|
| Exit Ebitda | $76.5M |
| Exit Ev | $802.9M |
| Net Debt At Exit | $212.0M |
| Equity At Exit | $591.0M |
| Equity Invested | $275.2M |
| Total Value Created | $315.8M |
| Value From Growth | $257.8M |
| Value From Multiple | $26.0M |
| Value From Deleveraging | $47.6M |